Zenotech Laboratories Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Thu Jan 22 2026

Zenotech Laboratories Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Zenotech Laboratories’ Q3 results FY26 are scheduled to be announced on 23rd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Zenotech Laboratories Q3 Results 2026 Preview

Zenotech Laboratories’ revenue is expected to be in the range of ₹11.24 crore, a 15.11% YoY increase.
Profit After Tax, or PAT, is projected to rise by 25.63% YoY.
Zenotech Laboratories’ EBITDA is expected to rise to ₹2.73 crore.
Net profit is ₹1.69 crore, up 25.63% YoY

Zenotech Laboratories Share Performance

Over the past six months, Zenotech Laboratories’ share price has fallen by 24.62% to ₹46.65.
Moreover, over the past year, the stock has decreased by 25.40%.
Despite this weak short-term performance, Zenotech Laboratories’ stock has delivered a financially sound 51.22% return over the past 5 years.
As of 22nd January 2026, the stock traded at ₹46.65 per share.

Key Factors to Watch for Zenotech Laboratories Q3 Results FY26

Revenue Trend: Whether net sales have grown or declined compared with recent quarters, given volatility in past quarterly sales.
Profitability Movement: Change in PAT — improvement, stability or further losses — as the company has swung between profits and losses recently.
Operating Margins: Trends in gross and operating margins, since margin compression has been a recent concern.
Cost & Expense Control: How well the company is managing costs like employee and production expenses vis-à-vis revenue performance.
Balance Sheet & Cash Position: Liquidity or net cash status, important for a small, niche injectable player with limited scale.

Final Thoughts

Zenotech Laboratories will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 15.11% YoY revenue growth, a 25.63% rise in PAT, and an 36.31% rise in EBITDA. Zenotech Laboratories focuses on developing and manufacturing specialty generic pharmaceutical injectables, particularly for oncology, biotechnology and anesthesiology applications, offering contract manufacturing and recombinant protein services with an emphasis on high-quality biotherapeutic and niche therapy products.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!